Back to search

Peptide record

TPDB12531

Antibacterial Anticancer Toxicity standard
12 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB12531
Antibacterial Anticancer Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia
standard
No
A 12-aa standard natural multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from AntiBP3 and Peptipedia, with an available 3D structural model.
Sequence
RWKIFKKIEKVG
Physicochemical Analysis
C74H122N20O15
ANDCQHLMPSTY
K
1531.91
10.98
5
1
5
+4
3.27
-0.742
89.17
Mammalian: 1 hour Yeast: 2 min E.coli: 2 min
5500
359.03
0
Residue Composition
number
0
A
1
R
0
N
0
D
0
C
1
E
0
Q
1
G
0
H
2
I
0
L
4
K
0
M
1
F
0
P
0
S
0
T
1
W
0
Y
1
V
Amino Acid Distribution
A: 0 R: 1 N: 0 D: 0 C: 0 E: 1 Q: 0 G: 1 H: 0 I: 2 L: 0 K: 4 M: 0 F: 1 P: 0 S: 0 T: 0 W: 1 Y: 0 V: 1
Chemical Descriptors
12
C74H122N20O15
1531.91
10.98
+4
3.27
-0.742
Evidence Records 3 records
Evidence 1 Activity

Activity

0% Killing
Toxicity
50 µM
Cytotoxic
0% Killing | 50 | µM | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Development of a novel short 12-meric papiliocin-derived peptide that is effective against Gram-negative sepsis. | Sci Rep | 2019
Evidence 2 Activity

Activity

0% Killing
Toxicity
50 µM
Cytotoxic
0% Killing | 50 | µM | target cell: Human embryonic kidney HEK293 cells

Target

Human embryonic kidney HEK293 cells

Source & Reference

NA
DBAASP
Development of a novel short 12-meric papiliocin-derived peptide that is effective against Gram-negative sepsis. | Sci Rep | 2019
Evidence 3 Activity

Activity

10% hemolysis
Toxicity
200 µM
Hemolytic Cytotoxic
10% hemolysis | 200 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Development of a novel short 12-meric papiliocin-derived peptide that is effective against Gram-negative sepsis. | Sci Rep | 2019